Treatment overview of axial spondyloarthritis in 2023

Management of extra‐articular manifestations in spondyloarthritis

(2023) Kevin Sheng‐Kai Ma et al.   International Journal of Rheumatic Diseases

Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?

(2023) S. R. Harrison et al.   Current Rheumatology Reports

OP0055 ASAS CONSENSUS DEFINITION OF EARLY AXIAL SPONDYLOARTHRITIS

(2023) V. Navarro-Compán et al.   ANNALS OF THE RHEUMATIC DISEASES

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

(2022) Steven R. Ytterberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort

(2022) Adrian Ciurea et al.   RMD Open

2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases

(2022) James M Gwinnutt et al.   ANNALS OF THE RHEUMATIC DISEASES

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis

(2022) Michael Nissen et al.   RHEUMATOLOGY

Treatment with Tumour Necrosis Factor Inhibitors is Associated with a Time‐Shifted Retardation of Radiographic Sacroiliitis Progression in Patients with Axial Spondyloarthritis: 10‐year Results from the German Spondyloarthritis Inception Cohort

(2022) Murat Torgutalp et al.   Arthritis & Rheumatology

OP0018 COMPARISON OF THE EFFECT OF TREATMENT WITH NSAIDs ADDED TO ANTI-TNF THERAPY VERSUS ANTI-TNF THERAPY ALONE ON PROGRESSION OF STRUCTURAL DAMAGE IN THE SPINE OVER TWO YEARS IN PATIENTS WITH ANKYLOSING SPONDYLITIS (CONSUL) – AN OPEN-LABEL, RANDOMIZED CONTROLLED, MULTICENTER TRIAL

(2022) F. Proft et al.   ANNALS OF THE RHEUMATIC DISEASES

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2022) Atul Deodhar et al.   LANCET

How is early spondyloarthritis defined in the literature? Results from a systematic review

(2022) Diego Benavent et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

(2022) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis

(2022) Casper Webers et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

(2022) Augusta Ortolan et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating spondyloarthritis early: does it matter? Results from a systematic literature review

(2022) Dafne Capelusnik et al.   RHEUMATOLOGY

The Risk Factors and Incidence of Major Infectious Diseases in Patients with Ankylosing Spondylitis Receiving Tumor Necrosis Factor Inhibitors

(2021) Bon San Koo et al.   Modern Rheumatology

Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis

(2021) Sizheng Steven Zhao et al.   RHEUMATOLOGY

TNF inhibitors reduce spinal radiographic progression in patients with radiographic axial spondyloarthritis: a longitudinal analysis from the ALBERTA FORCAST cohort

(2021) Alexandre Sepriano et al.   Arthritis & Rheumatology

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

(2021) Atul Deodhar et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial

(2021) Anna Molto et al.   ANNALS OF THE RHEUMATIC DISEASES

Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure

(2021) Hong Ki Min et al.   RHEUMATOLOGY

Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?

(2021) Ulf Lindström et al.   ANNALS OF THE RHEUMATIC DISEASES

Motivators, barriers, and opportunity for e‐health to encourage physical activity in axial spondyloarthritis: a qualitative descriptive study

(2021) Laura Passalent et al.   ARTHRITIS CARE & RESEARCH

Upadacitinib in Active Ankylosing Spondylitis: 1‐Year Results From the Double‐Blind, Placebo‐Controlled SELECT‐AXIS 1 Study and Open‐Label Extension

(2021) Atul Deodhar et al.   Arthritis & Rheumatology

European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response

(2021) Sara Nysom Christiansen et al.   RHEUMATOLOGY

Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study

(2021) T Rusman et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

The Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta‐Analysis

(2020) Paras Karmacharya et al.   Arthritis & Rheumatology

Immunogenicity of TNF-Inhibitors

(2020) Sadaf Atiqi et al.   Frontiers in Immunology

Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden

(2020) Tine Iskov Kopp et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

(2020) Iain B McInnes et al.   LANCET

Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort

(2020) Raphael Micheroli et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis

(2020) Ana Rita Cruz-Machado et al.   RHEUMATOLOGY

Do smoking and socioeconomic factors influence imaging outcomes in axial spondyloarthritis? Five‐year data from the DESIR cohort

(2020) Elena Nikiphorou et al.   Arthritis & Rheumatology

Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review

(2020) Pablo Antonio Zurita Prada et al.   CLINICAL RHEUMATOLOGY

One‐year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in Spondyloarthritis

(2020) Bente Glintborg et al.   ARTHRITIS CARE & RESEARCH

Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases

(2019) Bruno Laganà et al.   Frontiers in Pharmacology

High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients

(2019) Silje Halvorsen Sveaas et al.   BRITISH JOURNAL OF SPORTS MEDICINE

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

(2019) Stefan Schreiber et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of loss of correction between PSO and VCD technique in treating thoracolumbar kyphosis secondary to ankylosing spondylitis, a minimum 2 years follow-up

(2019) Yao Wang et al.   Journal of Orthopaedic Surgery and Research

Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration

(2019) Lykke Midtbøll Ørnbjerg et al.   ANNALS OF THE RHEUMATIC DISEASES

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

(2019) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

(2019) Michael M. Ward et al.   ARTHRITIS CARE & RESEARCH

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

(2019) Désirée van der Heijde et al.   LANCET

2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis

(2018) Anne-Kathrin Rausch Osthoff et al.   ANNALS OF THE RHEUMATIC DISEASES

Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort

(2018) Monika Hebeisen et al.   JOURNAL OF RHEUMATOLOGY

Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register

(2018) Gary J Macfarlane et al.   RHEUMATOLOGY

Barriers and facilitators of vigorous cardiorespiratory training in axial Spondyloarthritis: Surveys among patients, physiotherapists, rheumatologists

(2018) Karin Niedermann et al.   ARTHRITIS CARE & RESEARCH

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis

(2017) Ennio Lubrano et al.   JOURNAL OF RHEUMATOLOGY

Axial spondyloarthritis

(2017) Joachim Sieper et al.   LANCET

Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis

(2017) Atul Deodhar et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment With Tumor Necrosis Factor Inhibitors

(2017) Fiona Maas et al.   ARTHRITIS CARE & RESEARCH

Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers

(2016) Karin Hellgren et al.   ANNALS OF THE RHEUMATIC DISEASES

Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) data

(2016) Tae-Jong Kim et al.   JOINT BONE SPINE

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies

(2016) Omoniyi J. Adedokun et al.   Journal of Crohns & Colitis

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

(2016) Quan Dong Nguyen et al.   LANCET

Impact of Dose Tapering of Tumor Necrosis Factor Inhibitor on Radiographic Progression in Ankylosing Spondylitis

(2016) Jun Won Park et al.   PLoS One

Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis

(2016) Xenofon Baraliakos et al.   RHEUMATOLOGY

Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review

(2016) Victoria Navarro-Compán et al.   RHEUMATOLOGY

Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)

(2015) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis

(2015) Adrian Ciurea et al.   ANNALS OF THE RHEUMATIC DISEASES

Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort

(2014) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

The window of opportunity: a relevant concept for axial spondyloarthritis

(2014) Philip C Robinson et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial

(2013) H Haibel et al.   ANNALS OF THE RHEUMATIC DISEASES

Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis

(2013) Carmen Stolwijk et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study

(2013) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term health benefits of physical activity – a systematic review of longitudinal studies

(2013) Miriam Reiner et al.   BMC PUBLIC HEALTH

Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies

(2012) Irene E van der Horst-Bruinsma et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis

(2011) Denis Poddubnyy et al.   ARTHRITIS AND RHEUMATISM

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register

(2010) E. Lie et al.   ANNALS OF THE RHEUMATIC DISEASES

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

(2009) M Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis

(2009) Nick Barkham et al.   ARTHRITIS AND RHEUMATISM

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis

(2008) C Lukas et al.   ANNALS OF THE RHEUMATIC DISEASES